Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel-Reference-Cited by-同舟云学术

Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Published:2015-01-14 Issue:5 Volume:55 Page:497-504
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Kapitza Christoph¹,Nosek Leszek¹,Jensen Lene²,Hartvig Helle²,Jensen Christine B.²,Flint Anne²

Affiliation:

1. ProfilNeussGermany

2. Novo Nordisk A/SSøborgDenmark

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.443

Reference31 articles.

1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

2. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

3. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

4. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon‐like peptide‐1 (GLP‐1)‐(7–36) amide in type 2 (noninsulin‐dependent) diabetic patients;Willms B;J Clin Endocrinol Metab,1996

5. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEVELOPMENT AND VALIDATION OF A SPECIFIC AND UNIQUE DUAL POLARITY ESI-LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND DAPAGLIFLOZIN IN HUMAN PLASMA;International Journal of Applied Pharmaceutics;2024-09-07

2. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk;Nutrients;2024-08-28

3. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review;Cureus;2024-08-17

4. Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence;Physiology & Behavior;2024-07

5. Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases;Journal of Chromatography B;2024-07